Ixekizumab superior to ustekinumab in psoriasis treatment
Interleukin 17A (IL-17A) antagonist ixekizumab demonstrates superior efficacy and similar safety outcomes compared with IL-12/23 inhibitor ustekinumab through 52 weeks of treatment, according to the results of a phase III trial.
“Biologics targeting IL-17A allow for rapid clearance of psoriatic plaques, with a clinically favourable safety profile,” the authors said.
There were significantly more patients in the ixekizumab vs ustekinumab group who reported Psoriasis Area and Severity Index (PASI) score 90 (76.5 percent vs 59.0 percent), a static Physician's Global Assessment (sPGA) response of 0 (52.9 percent vs 36.1 percent), or an sPGA response of 0 or 1 (82.1 percent vs 65.1 percent) at week 52.
There were no significant between-group differences in treatment-emergent adverse events (AEs), serious AEs and discontinuation rates. Injection site reactions more frequently occurred among patients treated with ixekizumab vs ustekinumab (16.3 percent vs 1.2 percent; p<0.001).
This study sought to compare the efficacy and safety of ixekizumab with those of ustekinumab in the head-to-head trial IXORA-S. The authors randomly assigned patients to ixekizumab (n=136) or ustekinumab (n=166), dosed according to approved labels.
Efficacy was evaluated after 1 year via improvements in PASI score (with PASI 90 indicating ≥90-percent improvement from baseline) and an sPGA response of either 0 or 0 or 1, with dropouts counted as nonresponders. Safety analyses included treatment-emergent AEs.
“This study was not designed to compare safety endpoints related to rare events,” the authors said.